Briefing
ASCO 2026: serial Signatera positivity after week 12 tracked with worse outcomes on enfortumab vedotin
In 110 patients with advanced urothelial carcinoma treated with enfortumab vedotin with or without pembrolizumab, an ASCO 2026 analysis of serial Signatera testing associated ctDNA positivity after 12 weeks with worse progression-free survival (HR 36.8) and overall survival (HR 17.7).